DGIdb - EPIRUBICIN Drug Record

EPIRUBICIN chembl:CHEMBL417 ApprovedAntineoplasticImmunotherapy

Alternate Names:

NSC-256942
EPIRUBICIN
ELLENCE
4'-EPIADRIAMYCIN
PIDORUBICINE
EPIRUBICINE
EPIRUBICINA
EPIRUBICINUM
EPIADRIAMYCIN
PIDORUBICINUM
PIDORUBICINA
rxcui:3995
chembl:CHEMBL417
pubchem.compound:41867
chemidplus:56420-45-2
drugbank:00445

Drug Info:

Year of Approval	1999
Drug Class	antineoplastic agents
FDA Approval	1999
Drug Class	small molecule
Drug Indications	Antineoplastic Agents

(5 More Sources)

Publications:

Petit et al., 2004, Comparative value of tumour grade, hormonal receptors, Ki-67, HER-2 and topoisomerase II alpha status as predictive markers in breast cancer patients treated with neoadjuvant anthracycline-based chemotherapy., Eur. J. Cancer
Liang et al., 2007, Solamargine upregulation of Fas, downregulation of HER2, and enhancement of cytotoxicity using epirubicin in NSCLC cells., Mol Nutr Food Res
Knoop et al., 2005, retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group., J. Clin. Oncol.
Szkandera et al., 2012, Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer., Mol. Genet. Genomics
Bertheau et al., 2007, Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen., PLoS Med.
Sugishita M et al., 2016, Pharmacogenetic association between GSTP1 genetic polymorphism and febrile neutropenia in Japanese patients with early breast cancer., Breast Cancer
Zhang BL et al., 2011, Polymorphisms of GSTP1 is associated with differences of chemotherapy response and toxicity in breast cancer., Chin Med J (Engl)
Oliveira AL et al., 2010, GSTT1, GSTM1, and GSTP1 polymorphisms and chemotherapy response in locally advanced breast cancer., Genet Mol Res
Konecny et al., 2001, HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer., Breast Cancer Res. Treat.
Imming et al., 2006, Drugs, their targets and the nature and number of drug targets., Nat Rev Drug Discov
Overington et al., 2006, How many drug targets are there?, Nat Rev Drug Discov
Le Morvan V et al., 2015, Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial., Pharmacogenomics J
Abraham JE et al., 2014, Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel., Clin Cancer Res
Molnar et al., New silicon compounds as resistance modifiers against multidrug-resistant cancer cells., Anticancer Res.
Guan et al., 2006, [siRNA against survivin coupling with epirubicin enhances to induce breast cancer cell MCF-7 to apoptosis]., Sichuan Da Xue Xue Bao Yi Xue Ban
Chow et al., 2003, The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells., Breast Cancer Res. Treat.
Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer
Ladoire et al., 2012, FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial., Ann. Oncol.
Geng R et al., 2014, Oxidative stress-related genetic polymorphisms are associated with the prognosis of metastatic gastric cancer patients treated with epirubicin, oxaliplatin and 5-fluorouracil combination chemotherapy., PLoS One
Choi JY et al., 2009, Nitric oxide synthase variants and disease-free survival among treated and untreated breast cancer patients in a Southwest Oncology Group clinical trial., Clin Cancer Res
Demirkan et al., 2006, The effect of anthracycline-based (epirubicin) adjuvant chemotherapy on plasma TAFI and PAI-1 levels in operable breast cancer., Clin. Appl. Thromb. Hemost.

EPIRUBICIN CHD1

Interaction Score: 8.24

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284

Sources:
TdgClinicalTrial TEND
EPIRUBICIN FOXP3

Interaction Score: 1.37

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
22431701

Sources:
CIViC
EPIRUBICIN MDM4

Interaction Score: 0.82

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24958282

Sources:
PharmGKB
EPIRUBICIN FOXO1

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN PERP

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN PPP2R5D

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN GNL3

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN TP53AIP1

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN CCNK

Interaction Score: 0.69

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN HMMR

Interaction Score: 0.52

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN CBR3

Interaction Score: 0.41

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN RBX1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN PON1

Interaction Score: 0.34

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN IRS1

Interaction Score: 0.29

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN NOS3

Interaction Score: 0.28

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25545243 19671875

Sources:
PharmGKB
EPIRUBICIN CYP1B1

Interaction Score: 0.22

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
24958282 24599932

Sources:
PharmGKB
EPIRUBICIN SERPINE1

Interaction Score: 0.21

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16444429

Sources:
NCI
EPIRUBICIN GSTP1

Interaction Score: 0.17

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
25008867 21362365 20568049

Sources:
PharmGKB
EPIRUBICIN TOP2A

Interaction Score: 0.15

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
14728934 17639997 16234514

Sources:
TdgClinicalTrial TEND PharmGKB
EPIRUBICIN BIRC5

Interaction Score: 0.11

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
16608080

Sources:
NCI
EPIRUBICIN BCL2

Interaction Score: 0.1

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
14503796

Sources:
NCI
EPIRUBICIN SLCO1B1

Interaction Score: 0.08

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
27234217

Sources:
PharmGKB
EPIRUBICIN CYP19A1

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN PIK3R2

Interaction Score: 0.06

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN NOS1

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN TOP2B

Interaction Score: 0.05

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
TTD
EPIRUBICIN INSR

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
None found

Sources:
PharmGKB
EPIRUBICIN ERBB2

Interaction Score: 0.03

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
11759828

Sources:
NCI
EPIRUBICIN TP53

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

Evidence Type Actionable

Approval Status Phase I

Response Type sensitive

PMIDs:
22903472 17388661

Sources:
JAX-CKB PharmGKB
EPIRUBICIN ABCB1

Interaction Score: 0.02

Interaction Types & Directionality:

n/a

Interaction Info:

PMIDs:
15161039

Sources:
NCI

TEND: EPIRUBICIN
- Version: 01-August-2011
Alternate Names:

EPIRUBICIN Primary Drug Name

Drug Info:

Drug Class antineoplastic agents

Year of Approval 1999

Publications:
TdgClinicalTrial: EPIRUBICIN
- Version: January-2014
Alternate Names:

Drug Info:

Drug Indications Antineoplastic Agents

Drug Class small molecule

FDA Approval 1999

Publications:

NCI: EPIRUBICIN

Version: 14-September-2017

Alternate Names:

C474 NCI drug code

Drug Info:

Publications:

Molnar et al., New silicon compounds as resistance modifiers against multidrug-resistant cancer cells., Anticancer Res.

Chow et al., 2003, The differential effects of cyclophosphamide, epirubicin and 5-fluorouracil on apoptotic marker (CPP-32), pro-apoptotic protein (p21(WAF-1)) and anti-apoptotic protein (bcl-2) in breast cancer cells., Breast Cancer Res. Treat.

Guan et al., 2006, [siRNA against survivin coupling with epirubicin enhances to induce breast cancer cell MCF-7 to apoptosis]., Sichuan Da Xue Xue Bao Yi Xue Ban

JAX-CKB: Epirubicin
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Bertheau et al., 2007, Exquisite sensitivity of TP53 mutant and basal breast cancers to a dose-dense epirubicin-cyclophosphamide regimen., PLoS Med.
JAX-CKB: epirubicin
- Version: 27-September-2017
Alternate Names:

Drug Info:

Publications:

Szkandera et al., 2012, Analysis of functional germline polymorphisms for prediction of response to anthracycline-based neoadjuvant chemotherapy in breast cancer., Mol. Genet. Genomics

PharmGKB: epirubicin

Version: 18-August-2020

Alternate Names:

Drug Info:

Publications:

Abraham JE et al., 2014, Replication of genetic polymorphisms reported to be associated with taxane-related sensory neuropathy in patients with early breast cancer treated with Paclitaxel., Clin Cancer Res

Le Morvan V et al., 2015, Identification of SNPs associated with response of breast cancer patients to neoadjuvant chemotherapy in the EORTC-10994 randomized phase III trial., Pharmacogenomics J

Reimer T et al., 2016, SLCO1B1*5 polymorphism (rs4149056) is associated with chemotherapy-induced amenorrhea in premenopausal women with breast cancer: a prospective cohort study., BMC Cancer

CIViC: EPIRUBICIN

Version: 14-September-2020

Alternate Names:

Drug Info:

Publications:

Ladoire et al., 2012, FOXP3 expression in cancer cells and anthracyclines efficacy in patients with primary breast cancer treated with adjuvant chemotherapy in the phase III UNICANCER-PACS 01 trial., Ann. Oncol.

TTD: Epirubicin
- Version: 2020.06.01
Alternate Names:

D0C9XJ TTD Drug ID

Drug Info:

Publications:
ChemblDrugs: chembl:CHEMBL417
- Version: ChEMBL_27
Alternate Names:

Drug Info:

Publications:

Evidence Type	Actionable
Approval Status	Phase I
Response Type	sensitive

Trial Name	-
Novel drug target	Established target

EPIRUBICIN Drug Record

EPIRUBICIN chembl:CHEMBL417 ApprovedAntineoplasticImmunotherapy

Alternate Names:

Drug Info:

Publications:

Interaction Types & Directionality: antagonist (inhibitory)

Interaction Info: Trial Name - Novel drug target Established target

PMIDs: 17016423 17139284

Sources: TdgClinicalTrial TEND

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 22431701

Sources: CIViC

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24958282

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: None found

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25545243 19671875

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 24958282 24599932

Sources: PharmGKB

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 16444429

Sources: NCI

Interaction Types & Directionality: n/a

Interaction Info:

PMIDs: 25008867 21362365 20568049

Sources: PharmGKB

Interaction Types & Directionality: inhibitor (inhibitory)

Interaction Info: Novel drug target Established target Trial Name -

PMIDs: 14728934 17639997 16234514

Interaction Types & Directionality:

antagonist (inhibitory)

Interaction Info:

Trial Name -

Novel drug target Established target

PMIDs:
17016423 17139284

Sources:
TdgClinicalTrial TEND

Interaction Types & Directionality:

n/a

PMIDs:
22431701

Sources:
CIViC

Interaction Types & Directionality:

n/a

PMIDs:
24958282

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
25545243 19671875

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
24958282 24599932

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16444429

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
25008867 21362365 20568049

Sources:
PharmGKB

Interaction Types & Directionality:

inhibitor (inhibitory)

Interaction Info:

Novel drug target Established target

Trial Name -

PMIDs:
14728934 17639997 16234514

Sources:
TdgClinicalTrial TEND PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
16608080

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
14503796

Sources:
NCI

Interaction Types & Directionality:

n/a

PMIDs:
27234217

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
PharmGKB

Interaction Types & Directionality:

n/a

PMIDs:
None found

Sources:
TTD